WallachBeth Capital Reiterates “Buy” Rating for Clovis Oncology (CLVS)
Clovis Oncology (NASDAQ:CLVS)‘s stock had its “buy” rating reaffirmed by equities researchers at WallachBeth Capital in a research report issued on Tuesday. They currently have a $85.00 price target on the stock. WallachBeth Capital’s price objective points to a potential upside of 49.73% from the stock’s previous close.
A number of other firms have also recently commented on CLVS. Analysts at Goldman Sachs initiated coverage on shares of Clovis Oncology in a research note on Monday, March 24th. They set a “neutral” rating and a $90.00 price target on the stock. Separately, analysts at Credit Suisse raised their price target on shares of Clovis Oncology from $78.00 to $100.00 in a research note on Wednesday, March 5th. Finally, analysts at Leerink Swann raised their price target on shares of Clovis Oncology from $104.00 to $110.00 in a research note on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $89.57.
Clovis Oncology (NASDAQ:CLVS) opened at 56.77 on Tuesday. Clovis Oncology has a 1-year low of $32.32 and a 1-year high of $93.33. The stock has a 50-day moving average of $56.98 and a 200-day moving average of $63.63. The company’s market cap is $1.925 billion.
Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Thursday, May 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.06. The company had revenue of $13.60 million for the quarter. Analysts expect that Clovis Oncology will post $-3.89 EPS for the current fiscal year.
Clovis Oncology, Inc is a United States-based biopharmaceutical company. The Company develops anti-cancer agents.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.